Latest news with #OptimumNutrition
Irish Examiner
17-05-2025
- Sport
- Irish Examiner
Kerry experience inspired Gavin Crowley's tech business venture
As he progressed through the underage levels with Kerry, Gavin Crowley would often wonder why some standout players from the younger grades were no longer involved. The Templenoe man joined Kerry's underage development squads at U14, and progressed all the way to senior level, starting the drawn 2019 All-Ireland final and replay, and being part of the Sam Maguire winning panel of 2022. 'They could be your friends as you're growing up, then you reach minor level and some of them aren't making it, or some of them are dropping out of football," says Crowley. "You think that this guy at minor level is definitely going to make it at senior but never did.' It wasn't until Crowley did a degree in Health and Leisure at MTU Kerry that he realised the promise those players had shown at a young age was ultimately their downfall. They were being pulled from all directions by too many teams. 'Maybe they got injured or got sick of playing because they were being overloaded - not just physically but mentally overloaded - and the enjoyment fell away,' he says. 'Maybe they lost interest because they were getting injured all the time. You probably have lads, 14-years-old, but they're playing with the U16s as well in every sport. They could have been playing on 10 different teams at a young age. 'You just wonder if those players were looked after better, would they have gone on and played at senior inter-county level? Possibly.' The experience inspired him to do a research masters in youth load monitoring, and last week launch YouMon, an app which he believes can help players better navigate the bumpy underage sport road. YouMon allows players, their parents and coaches to monitor workload, injuries and schedules. They can keep tabs on growth rates and maturation. It also provides a safe method of communication between players and coaches. 'The main thing I wanted to combat was players playing multiple sports but the coaches aren't talking to each other,' says Crowley. 'That's really the core of why I developed YouMon.' Since the launch, Crowley has been blown away by the traffic to their website, and the enquiries from those looking for demonstrations. The app had been 'three or four years' in development. He's now onto a different stage: Marketing. Getting customers and turning this into a profitable business is the next step. Two years spent working with Optimum Nutrition has given him some sales experience. Crowley works as a personal trainer at a gym in Kenmare. That takes up his mornings and evenings. In between, he works on YouMon. Being a parent to two children takes up everything else. 'Playing with Kerry, it does give you that sense of confidence to do things by yourself,' he says. 'If I hadn't played with Kerry, I don't know if I would have had the confidence to launch an app like this myself. If I hadn't played with Kerry, would I have had this idea? Probably not. 'A big thing for me was that I had highly experienced coaches. You have the likes of Jason McGahan and Fionn Fitzgerald who are experts in their fields. The fact I played with Kerry, had access to those coaches, it was a great help that I was able to bounce the ideas off them.' It's two years since Crowley retired from inter-county football. There was no statement. He slipped off quietly after the 2023 National League knowing nothing could top lifting Sam Maguire with his son the previous July. Jack O'Connor was 'very accommodating'. The manager understood the player's reasons. 'I retired from Kerry when I was 29,' says Crowley. 'That's probably young for most people but considering I started playing with Kerry at 14, it seems like a long time. Could I have gone on for longer? Possibly. 'I felt I wasn't able to give 100% to Kerry anymore. I had other commitments: a small child, a wife. You're thinking that you love Kerry so much that if I wasn't able to give 100%, you're better off giving someone who can their go at it. 'Looking back, if you're playing every day, you're starting every time, you are more likely to stick at it. If you're not playing as much as you want, you have to weigh up if it's worth it anymore. 'It's when you step away that you look back and think about the amount of commitment that's involved at that level, the amount of days and nights of effort those lads put in is crazy. You have huge respect for the lads that are in there now. If you're not able to give your all to it, you can get left behind fairly fast.' Crowley is now giving his all to ensure young players, like his friends in those development squads nearly two decades ago, don't get left behind. You can find out more at or by emailing gavin@
Irish Times
02-05-2025
- Business
- Irish Times
What's gone wrong at Glanbia?
It's hard to pinpoint exactly what's gone wrong at Glanbia . There are several partial explanations, but no real smoking gun, nothing that can fully explain why the company's share price is now back at the same level it was 12 years ago (€11) when the group today is larger with more assets. [ ] Or why the Kilkenny-based nutritionals group has shed more than €2 billion in market value in less than 10 months despite holding one of the bestselling protein powder brands on the market in Optimum Nutrition, sponsor of the McLaren Formula One team. Protein powders used to be the preserve of bodybuilders and workout fanatics, now every Tom, Dick and Harry is using them and the company should be prospering as a result. READ MORE Critics say Glanbia is primarily a B2B (business-to-business) ingredients company that has strayed too far from its core competencies. Said another way, it is not good at managing consumer-facing brands. Glanbia's performance nutrition business, which accounts for more than half of earnings, is made up of several add-on brands (Optimum Nutrition, Isopure, BSN, Nutramino, Think Thin, SlimFast, LevlUp, Body&Fit) that it has picked up along the way, most of which have declined in value since entering the Glanbia stable. Even its prize pony, Optimum Nutrition, is said to be operating below potential. One institutional shareholder says the company does not have the distribution channels of a Coca-Cola or a Nestlé to get these products to consumers and that's why they have failed to fire. That distribution channel issue may also explain why it has been slow to move beyond basic powders and into the fast-growing protein drinks market. Another line of criticism suggests the company has simply presided over a string of bad buys, which have failed to add value to the group. The market values these acquisitions at a fraction of the price the company paid for them. These deals culminated in the acquisition of weight-loss brand SlimFast in 2018 for $350 million (€309 million). The company reported a non-cash impairment charge of $91 million last year relating to declining sales at its SlimFast unit. The SlimFast fad of the 1980s and 1990s has waned , not least because of concerns about replacing wholefoods with highly processed synthetic shakes – a no-no for nutritionists. Consumers are also opting for more active weight-loss programmes rather than passive meal-replacement regimes, calling into question Glanbia's purchase of the brand in the first place. SlimFast is now the subject of a fire-sale auction and is likely to sell for a fraction of the $350 million Glanbia paid for the business. The company clearly doesn't think it has a bad M&A (mergers and acquisitions) report card as it elevated the man responsible for most of these deals, Hugh McGuire (formerly the head of the company's performance nutrition division), to the top job last year. He succeeded Siobhán Talbot in the top role. The third and perhaps most trenchant line of criticism, and the one that a growing number of institutional investors have latched on to, is that the company has become an unwieldy 'Frankenstein'. Glanbia's complex corporate structure, which oversees three disparate businesses in the sports nutrition, ingredients and dairy categories, has become too difficult to manage, they say. The company's communications team spends a lot of time explaining the various parts and where they sit. 'The sprawling corporate structure with a lot of moving parts, three very good, excellent but very different businesses make Glanbia very hard to value, complicated to understand and possibly and arguably difficult to manage,' the head of Clearway Capital, Gianluca Ferrari, told the company's AGM in the Kilashee Hotel in Co Kildare this week. Clearway Capital holds about 1 per cent of Glanbia shares. 'There's an obvious solution to this: separate the businesses,' Ferrari said. Glanbia has long maintained that a strategy of diversification would help insulate the business, but investors now highlight this as a key weakness. Ferrari said 'the argument that diversification would shield the business from volatility has proved to be blatantly false'. 'The structure itself is causing the volatility [in the share price],' he said. The assertion comes after the company's recent profit warning, linked to higher-than-expected whey prices, which are expected to knock $75 million off annual earnings (roughly 13 per cent), triggered an immediate 25 per cent downturn in the share price. Ferrari's point is that Glanbia's messy conglomerate structure is amplifying these shocks rather than limiting them. Of course, the ugliest metric and the one raised by several disgruntled shareholders at the AGM relates to the generous pay and bonuses doled out to those who have presided over this underperformance. Glanbia has paid €81 million in total director remuneration over the past decade. This has coincided with what Roland French of Penman Securities, another institutional investor, said was a total shareholder return, including dividends, of 'minus' 36 per cent. 'If you benchmark this globally whether that's Euro Stoxx or S&P, that's in the bottom decile in a 10-year performance context,' he said. 'A 10-year performance window should be more than sufficient for any board of directors to conclude something is not functioning.' Glanbia gave Talbot a parting salary plus bonus of €8 million in 2023. The group's chief financial officer Mark Garvey, still in situ, took home €3.6 million that year. Talbot, the person at the helm for most of the past 10 years, got out before the current storm, leaving her successor, McGuire, firmly in the crosshairs of angry shareholders. McGuire insists the company is on the back foot because of an unprecedented surge in whey prices, which he described as a 'perfect storm of demand and supply', but one which is also 'cyclical'. 'Whey costs rose last year and continued to rise in January and February of this year to reach record levels,' the company said in response to a query. 'We have never seen this level of dairy inflation before. We have done a lot of work around mitigating the impact of this inflation and, as we said this morning, we have seen whey protein isolate come off its peak pricing.' At the AGM, Kilkenny dairy farmer Michael O'Carroll hit back at the company's suggestion that it was caught out by the high cost of whey, saying that if Ryanair chief Michael O'Leary said the company's share price had been halved 'because he hadn't hedged his fuel price, he'd be sacked in the morning'. The company also defends its M&A record, suggesting the 'return on capital' is a closely watched metric. 'Glanbia's average return on capital employed metric (ROCE) for the last three years is well within our medium-term target range 10-13 per cent,' it said. 'We have taken the decision to sell two brands {SlimFast and Body&Fit] in line with our commitment to continuous evaluating our portfolio. 'The rationale for both divestments is clear and is linked to changing consumer behaviour around weight loss in the case of SlimFast and the changing economics of owning a direct-to-consumer ecommerce platform in the case of Body&Fit.' It also noted that Optimum Nutrition and Isopure have performed 'very well'. The big beast among shareholders and the one that has sat silently while Glanbia's share price has plunged over the last year is Tirlán , the farmer-led co-op that operates the group's legacy dairy business here, which was spun-out in a series of transactions over the past decade. Tirlán owns 29 per cent of Glanbia. One investor called it a one-stock hedge fund. Ferrari wrote to Tirlán earlier this year in an attempt to enlist its support for a strategic review of the Glanbia business . He wrote that a 'fundamental strategic review focused on separating Glanbia's distinct business units is not only overdue but essential'. 'With the upcoming Glanbia and Tirlán AGMs in April and May 2025 respectively, there is a critical window of opportunity to signal to all stakeholders that Glanbia's largest shareholder is committed to restoring value and strategic clarity,' his letter said. Tirlán's AGM's next week might prove fierier than Glanbia's for two reasons. The co-op is spinning out Glanbia shares to members. The plan was announced when Glanbia shares were trading at close to €16, meaning the average member payout would have been €24,600. Now they will be receiving significantly less, 30 per cent less. On top of that, Tirlán has issued a convertible bond that matures in January 2027. Owners of the bond can convert their holding – on maturity – into Glanbia shares at a guaranteed conversion price. If the Glanbia share price is lower than €16.43, then Tirlán will be forced to make up the difference in cash. The guaranteed conversion price looked like an decent bet a few years ago, but with Glanbia shares down at €11 that's not the case any more. Ironically, the poor performance of Glanbia shares means Tirlán may be forced to further dilute its shareholding in Glanbia to fund the payout of its bond. That said, Tirlán, as Glanbia's largest shareholder, has the power to force change upon the board. Whether it will join other institutional shareholders in calling for the company to be split up remains to be seen, but the status quo is getting harder and harder to justify.
Reuters
30-04-2025
- Business
- Reuters
Glanbia shares jump after 'better than feared' first quarter
Summary Companies Full year guidance reiterated following February profit warning Whey costs down from peak, keeps full year profit margin forecast Sees resilient protein product sales in US Shares up 10% DUBLIN, April 30 (Reuters) - Shares in nutrition supplement maker Glanbia (GL9.I), opens new tab jumped 10% on Wednesday after analysts pointed to a "better than feared" first quarter performance that allowed the Irish group to maintain its full year earnings guidance. Glanbia shares plummeted to a near two-year low in February when it forecast that earnings could fall by up to 11% this year due to a prolonged rise in the cost of whey - a key ingredient in the protein powders and shakes popular with gym goers. It said on Wednesday that while whey prices remain elevated, they had come off their peak and it had bought enough to see it through to the fourth quarter and retain its full year margin expectations for its performance nutrition business. While first quarter group revenue grew by 7.2% year-on-year, performance nutrition fell 6.6% with its large Optimum Nutrition protein powder brand down 3.1% due to lower sales in U.S. fitness clubs that Glanbia had flagged in advance. Analysts at Davy Stockbrokers had expected Optimum Nutrition sales to fall by 14% in the quarter and Goodbody Stockbrokers said the overall outcome was "better than feared." The analysts were also encouraged by a 0.4% increase in U.S. consumption of Optimum Nutrition. Glanbia CEO Hugh McGuire said while he was very aware consumer confidence was falling in the U.S., protein products remain a resilient category. Glanbia also said it had largely mitigated its exposure to tariffs through price increases and plans to sell U.S manufactured products earmarked for China into alternative markets. Shares in the company were 9.8% higher at 0830 GMT, trimming the year-to-date loss to 16.7%. Goodbody said a fuller recovery was unlikely until sustained improvement is seen at half year. Asked on an analyst call about activist investor Clearway Capital's call for a break up of the company, McGuire said Glanbia would listen to all shareholder proposals and that there were "no sacred cows" as it looks to continuously create value. McGuire added that the planned sale of its underperforming U.S. weight management brand SlimFast is at the early stages.
Irish Times
30-04-2025
- Business
- Irish Times
Glanbia reiterates guidance ahead of AGM showdown
Glanbia reiterated its full year guidance for the year, even as sales at its performance nutritionals business dipped in the first three months of the year. The company, which is facing an activist investor calling for the possible break up of the company, said like-for-like revenue for the first quarter grew 4.5 per cent compared to a year ago. That came even as sales at its performance nutritionals unit fell 6.6 per cent. Its key Optimum Nutrition brand saw sales fall 3.1 per cent. £With the first quarter having progressed as planned, and whilst noting the ongoing uncertainty in relation to direct tariffs, we are pleased to reiterate our 2025 full year guidance of adjusted EPS2 in the range of 124 US cent – 130 US cent (-11 per cent to -7 per cent constant currency)," chief executive Hugh Maguire said. READ MORE Glanbia holds its AGM later today. Earlier this week a German activist investor, Clearway Capital wrote to the board of Tirlán Co-operative Society, the nutrition group's largest shareholder, in a bid to enlist support for a campaign for the business to carry out a strategic review after a share price slump.
Malaysian Reserve
23-04-2025
- Health
- Malaysian Reserve
Global Nutraceuticals Market to Grow by USD 668 Billion by 20233, Driven by Innovation, Consumer Demand, and Preventive Health Trends Says Astute Analytica
CHICAGO, April 23, 2025 /PRNewswire/ — The global nutraceuticals market was valued at USD 348 billion in 2024 and is projected to reach USD 668 billion by 2033, growing at a CAGR of 7.5%. This growth is underpinned by rising demand for convenient, health-focused products such as protein bars, fortified snacks, and meal replacements. Companies like Optimum Nutrition, MegaFood, and Garden of Life are leading innovation across sports nutrition, healthy aging, and cognitive wellness. Nutraceuticals are increasingly becoming central to holistic health routines, offering preventive benefits for noncommunicable diseases (NCDs) such as obesity, diabetes, and cardiovascular disorders. The World Health Organization estimates that over 1 billion people were obese in 2023, while diabetes affects more than 537 million adults globally – figures expected to rise steadily in the coming years. This growing burden is intensifying the demand for proactive health solutions such as dietary supplements. According to a 2020 study, 54% of diabetic patients reported using dietary supplements, with usage rates of 30% among those aged 20–39, 51% in the 40–64 age group, and 62% in individuals over 65. Supplement use was also more prevalent among females (57%) than males (50%). Among the nutraceuticals consumed, berberine has gained attention for its scientifically supported ability to significantly lower fasting blood glucose levels without increasing the risk of hypoglycaemia, making it a promising option in diabetes management. Request Sample Pages: The COVID-19 pandemic marked a turning point, accelerating consumer interest in immunity-boosting supplements. Products containing vitamin C, D, zinc, and other immune-supporting ingredients saw record sales. Leading brands like GNC, Herbalife, and Nature's Bounty responded swiftly with expanded product lines. Beyond immune health, the market has seen increased demand for stress relief, gut health, and energy-enhancing supplements. This sustained shift toward proactive health has cemented nutraceuticals as a core component of daily wellness for many consumers, even in the post-pandemic era. However, the industry faces ongoing challenges. Regulatory inconsistencies, particularly between regions, continue to pose hurdles. In the U.S., the Dietary Supplement Health and Education Act (DSHEA) of 1994 limits the FDA's oversight, allowing supplements to be sold without pre-market approval. This has raised quality concerns, highlighted by a 2015 investigation showing 79% of herbal supplements lacked the labelled ingredients. Similarly, while India's FSSAI has issued guidelines, enforcement varies widely. Supply chain dependencies also remain a risk, with 75–80% of ingredients being imported, making the industry vulnerable to disruptions, contamination, and quality control issues. To address these concerns, companies are increasingly adopting third-party certifications such as USP and NSF International to ensure transparency and build consumer trust. As the demand for science-backed and reliable supplements grows, the market consumers are becoming increasingly discerning in their nutraceutical choices, showing a strong preference for products backed by clinical evidence of safety and efficacy. Awareness of insufficient scientific validation significantly reduces their likelihood of purchase. Notably, consumers are willing to pay a premium – USD 252 more for products proven to have no side effects and USD 198 more for those with demonstrated effectiveness. Despite regulatory and supply chain challenges, the nutraceuticals industry is poised for sustained growth. With rising health consciousness, chronic disease prevalence, and innovations in personalized nutrition, nutraceuticals are set to play a key role in the future of preventive healthcare. Companies that prioritize safety, efficacy, and transparency are well-positioned to lead this expanding global market. Top Drivers • Rising Demand from Health-Conscious and Aging Populations Consumers • Increasing Prevalence of Lifestyle-related Diseases • Rising Demand of Personalized Nutrition Top Opportunities • The Rise of AI – Powered Personalized Nutraceuticals • Strategic Collaborations Between Pharma and Nutrition Companies • Integration of AI, Wearables, and Digital Health Platforms to personalize and optimize nutraceutical interventions Top Challenges • Regulatory Guidelines and Compliance Gaps • Quality Control & Raw Material Sourcing AI-Powered Personalization: Transforming the Nutraceutical Industry Advancements in artificial intelligence (AI), nanotechnology, and omics sciences are reshaping the nutraceutical landscape, driving a shift from generic wellness products to highly personalized, and data-driven health solutions. Consumers are increasingly prioritizing precision health, seeking tailored supplementation rather than a one-size-fits-all approach. This demand is reflected in a 2023 survey by the Nutritional Business Journal, which reported that 62% of consumers prefer personalized supplement plans. Companies like Bioniq are at the forefront of this evolution, utilizing AI-powered algorithms and biochemical databases to develop supplements customized based on blood markers, lifestyle habits, and specific health goals. Meanwhile, omics technologies are allowing for more effective formulation by improving nutrient bioavailability and targeting. For example, platforms like Nuritas's Magnifier employ deep learning to discover novel plant-based peptides with specific health benefits, such as anti-inflammatory properties for managing chronic conditions. Wearable devices are also playing a pivotal role by providing real-time physiological data – through tools like continuous glucose monitors, Oura Rings, and EEG sensors – that can dynamically inform and optimize supplement regimens. For instance, continuous glucose monitors (CGMs) like Dexcom G6 or Freestyle Libre help evaluate the impact of supplements such as berberine or chromium on blood sugar levels. The Oura Ring, which tracks sleep, heart rate variability (HRV), and body temperature, can be used to assess how magnesium or melatonin influences sleep quality and recovery. Likewise, portable EEG headbands like Muse provide brainwave feedback to determine the cognitive effects of nootropic supplements like L-theanine or ashwagandha. Complementing these developments, nanotechnology is revolutionizing nutrient delivery through micro-dosing techniques that enhance solubility, absorption, and stability. Innovative formats, such as oral nutraceutical pouches that dissolve between the gum and lip, are offering consumers convenient and fast-acting alternatives to traditional pills and powders, with Alpha Nootropic pouches standing out for their cognitive performance the growing prevalence of obesity and lifestyle-related diseases is significantly boosting the demand for natural and functional nutrition, creating strong momentum in the nutraceutical market. Since 1975, global obesity rates have nearly tripled, and by 2023, over 1 billion individuals were classified as obese. In the U.S., the situation is particularly concerning, with over 60% of adults and more than 30% of children and adolescents considered overweight or obese. A large proportion of these individuals – 45% of those who are overweight and 67% of those with obesity – are actively pursuing weight loss strategies. This has led to a surge in the use of nutraceuticals, especially dietary supplements aimed at weight management. Products like fat burners, appetite suppressants, and metabolism boosters are now commonly used, with around 15% of U.S. adults having tried weight-loss supplements, and usage notably higher among women (21%) than men (10%). As personalized AI platforms, advanced ingredient recovery, and innovative delivery system converge, the nutraceutical industry is entering a new phase of precision wellness. . This ongoing integration of emerging technologies is not only reshaping consumer expectations but also laying the groundwork for a future where personalized nutrition becomes a cornerstone of preventive healthcare and long-term health optimization. Global Nutraceutical Market Surge: Regional Trends Shaping Consumer Health Choices Regional dynamics are playing an increasingly pivotal role in the growth and diversification of the global nutraceutical market. While rising health consciousness, shifting consumer preferences, and evolving regulations continue to fuel overall market expansion, distinct trends and drivers are emerging across key regions. North America leads the way, supported by high consumer awareness, progressive policies such as the Dietary Supplement Health and Education Act (DSHEA) of 1994, and strong industry players like ADM and Cargill investing in areas such as probiotics, prebiotics, and plant-based proteins. The region's regulatory flexibility and rising chronic disease burden are accelerating demand for preventive health solutions. Europe follows closely, driven by a rapidly aging population, stringent but supportive regulation from the European Food Safety Authority (EFSA), and consumer demand for clean-label, clinically backed supplements. Markets in Germany, the UK, and France stand out, with major companies like Nestlé and Danone emphasizing scientific validation and sustainability. Meanwhile, Asia-Pacific is witnessing explosive growth due to rising income levels, increased health awareness, and demographic shifts. Economic progress in China and India is fueling demand for fortified foods and Western-style supplements, even as traditional remedies maintain popularity. Brands like Nestlé, Amul, and Dabur are successfully blending local health traditions with modern wellness trends, supported by the growth of e-commerce and personalized nutrition technologies. In contrast, the Middle East & Africa and Latin America are emerging markets with strong long-term potential. Though currently challenged by regulatory inconsistencies and infrastructure limitations, these regions are attracting increasing investment. As health awareness and regulatory frameworks improve, they are poised to become important contributors to the future of global nutraceutical innovation and consumption. Strategic Acquisitions and Advancements in Nutraceuticals Market Several major companies, including Nestlé Health Science, Danone S.A., BASF SE, Herbalife Nutrition, Archer Daniels Midland Company (ADM), DSM (Royal DSM N.V.), Herbalife Laboratories, United Laboratories, Amway, Arkopharma, Lifevision Healthcare, Uniray Lifescience, E.I.D. – Parry (India) Limited, and Zoic Pharmaceuticals, are driving innovation and growth in nutraceuticals market. These companies are advancing the field through strategic acquisitions, scientific discoveries, and collaborative ventures aimed at enhancing health outcomes and expanding global reach. For example, in October 2024, Keurig Dr Pepper (KDP) acquired a 60% stake in energy drink brand GHOST, with plans to acquire the remaining 40% by 2028. The deal positions GHOST under KDP's U.S. Refreshment Beverages division, with its co-founders maintaining leadership roles to preserve brand identity and momentum. Similarly, in December 2024, Nestlé announced a breakthrough in muscle health, identifying Nicotinamide and Pyridoxine as bioactive nutrients that activate muscle stem cells to enhance regeneration and strength recovery – paving the way for targeted innovations in aging and performance health. In another significant development, Danone completed the acquisition of Functional Formularies in May 2024, strengthening its Medical Nutrition portfolio in the U.S. and supporting its Renew Danone strategic transformation. Additionally, on April 25, 2024, Nestlé India and Dr. Reddy's Laboratories launched a joint venture focused on developing and distributing nutraceutical products across India and select global markets. The collaboration targets key health areas such as metabolic wellness, general nutrition, and paediatric care. Highlighting the role of science-driven product development, on May 14, 2024, Evonik introduced AvailOm a clinically validated omega-3 powder enhanced with Boswellia serrata for joint health. This innovative formulation has demonstrated efficacy in both in vitro and clinical studies, emphasizing the integration of scientific research into consumer products. These strategic moves and scientific advancements are reshaping the consumer health and nutrition sector, fueling market expansion, enhancing product efficacy, and establishing new standards for health-focused solutions worldwide. Inquiry Before Buying: The Nutraceuticals Market: Innovation, Personalization, and Future Growth The nutraceuticals market is poised for significant transformation, fuelled by technological innovation, shifting consumer expectations, and increasing emphasis on scientific validation. Growing awareness of preventive health, the rise in chronic lifestyle diseases, and demand for holistic wellness solutions are creating compelling opportunities for nutraceutical companies, pharmaceutical firms, and digital health platforms to redefine health management strategies. Experts forecast strong growth in personalized nutrition and functional food products, with advancements in artificial intelligence (AI), biomarker diagnostics, and delivery formats at the core of this evolution. The integration of AI-driven personalization tools is set to revolutionize consumer engagement and product efficacy. Companies like InsideTracker and Baze are leveraging biomarker analysis to deliver highly tailored supplement regimens, helping consumers make more informed health decisions. Meanwhile, evolving preferences for convenience and user-friendly products are driving innovation in supplement delivery systems. Formats such as gummies, dissolvable strips, effervescent tablets, and liquid shots are reshaping product design and gaining popularity across demographics. In parallel, the emergence of 'pharma foods' – nutritional products offering therapeutic benefits – is expected to expand the clinical relevance of nutraceuticals, particularly in the management of chronic diseases. The aging global population is also contributing to increased demand for ingredients that support longevity, joint health, skin elasticity, and immune function, such as collagen, antioxidants, and adaptogens. As personalized and functional wellness becomes mainstream, brands are presented with lucrative avenues for product diversification and consumer targeting. While traditional tablets and capsules will continue to dominate due to their precision and formulation stability, the market share of alternative formats is expected to grow rapidly. Gummies, in particular, are gaining traction thanks to their palatability and multifunctional ingredients, with brands like Olly and SmartyPants leading innovation in segments including immunity, beauty, and digestive health. The distribution landscape is also evolving into a hybrid retail model, balancing trust and accessibility. Brick-and-mortar channels such as pharmacies and supermarkets remain vital for in-person guidance and quality assurance, while e-commerce platforms offer wider reach, especially in remote or underserved regions. This omnichannel approach will be key to capturing diverse consumer segments and ensuring consistent brand engagement. On the regulatory front, increasing oversight from global health agencies is anticipated to shape market dynamics. Stricter safety standards, enhanced labelling regulations, and the integration of AI-powered quality control are expected to raise product transparency, reduce counterfeit risks, and build consumer trust. These developments will also support long-term industry credibility and facilitate the international expansion of reputable brands. By 2030, nutraceuticals are projected to play an integral role in global healthcare strategies, bridging the gap between nutrition and medicine. The success of this evolution will hinge on continued investment in scientific research, clinical validation, and regulatory compliance, ensuring that innovative and effective health solutions become accessible to a broader population. As novel delivery technologies, AI integration, and consumer-centric formulations gain momentum, the nutraceuticals market is set to emerge as a cornerstone of future wellness ecosystems. Key Competitors in the Nutraceutical Market: Nestlé Health Science Danone S.A. BASF SE Herbalife Nutrition Archer Daniels Midland Company (ADM) DSM (Royal DSM N.V.) Herbalife Laboratories United Laboratories Amway Freedom Food Group Limited The Hain Celestial Group Otsuka pharmaceutical co ltd General Mills Inc. Barilla Group Pfizer Bayer Sanofi Segmentation Overview By Product Type Dietary Supplements Functional Foods Functional Beverages Energy Drinks Sports Drinks Protein & Meal Replacement Drinks Yogurt Beverages Others By Ingredient Type Aloe Vera Amino Acids Botanical Ingredients Ashwagandha Curcumin Ginseng Hemp Others Astaxanthin Lutein Lycopene Other Carotenoids Calcium Iron Magnesium Selenium Others Marine-Derived Plant-Derived Stevia Monk Fruit Others Vitamin A Vitamin B Complex (B1, B2, B3, B5, B6, B9, B12) Vitamin C Vitamin D Vitamin E Vitamin K By Form Capsules Gummies Tablets Powders Gel Juice Cream By Application General Wellness Bone & Joint Health Skin, Hair & Nail Health Weight Management Reproductive Health Cognitive Health Antioxidant Support Aging & Longevity Neurological Disorders Eye Health Diabetes Management Cardiovascular Health Cancer Support Oral Health Radiotherapy Support Obesity Control Osteoarthritis Management By Distribution Channel Online Distribution E-commerce Platforms Official Brand Websites Offline Distribution Supermarkets & Hypermarkets Pharmacies & Drugstores E-commerce Platforms Official Brand Websites Supermarkets & Hypermarkets Pharmacies & Drugstores By Geography North America Europe Asia Pacific Middle East & Africa South America Get Customization on this Report: Explore More Reports: FemTech Market: By Offering (Equipment, Digital Platforms/Applications, and Services); Applications (Reproductive Health & Contraception, Pregnancy & Nursing, Menstrual Health, Mental Health, General Health & Wellness, and Others); Distribution Channel (Retail, Online); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Ultrasound Devices Market: By technology (Diagnostic Ultrasound, Therapeutic Ultrasound); Display Type (Color Ultrasound Devices and Black and White (B/W) Ultrasound Devices); Portability (Trolley/Cart-based Ultrasound Devices, Compact/Handheld Ultrasound Devices, and Point-of-care Ultrasound Devices); Application (Radiology/General Imaging, Cardiology, Gynecology, Vascular, Urology, Others); End Users (Hospitals, Surgical Centers, Diagnostic Centers, Ambulatory Surgical Centers, Maternity Centers, Others); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Recycled Carbon Fiber Market: By Type (Chopped recycled carbon fiber and Milled recycled carbon fiber); Source (Automotive, Aerospace, and Others); Process (Pyrolysis and Solvolysis); Application (Automotive, Wind Energy, Civil Engineering, 3D Printing, Energy Storage, Sporting Goods, Marine, Thermoplastic Compounding, Oil & Gas, Pressure Vessels, Aerospace and Defense, and Others); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Brain Computer Interface Market: By Component (Hardware, Software, Services); Type (Invasive BCI, Non-Invasive BCI, Partially Invasive BCI); Application (Healthcare, Gaming & Entertainment, Smart Home Control, Education & Research, Military & Defense, Others); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 About Astute Analytica Astute Analytica is a globally recognized market research and advisory firm, delivering data-driven insights and strategic intelligence to organizations worldwide. We offer comprehensive research solutions across a wide range of industries, including technology, healthcare, chemicals, semiconductors, FMCG, and more. Our reports provide in-depth analysis of market trends, competitive landscapes, emerging opportunities, and technological advancements, empowering businesses to make informed decisions in an evolving global environment. Supported by a team of seasoned analysts, economists, and industry experts, we are committed to delivering accurate, timely, and actionable insights. At Astute Analytica, client success is our priority. We offer customized research solutions that are both cost-effective and tailored to meet the unique needs of our clients. Contact:Mr. Vipin SinghAstute Analytica500 N Michigan Ave, Suite 600Chicago, Illinois, United StatesUSA: +1-888 429 6757Email: sales@ our Website: Website: Network Platform: Logo: View original content:
